Industry news

Development trend of the world bio pharmaceutical industry

Time：2017-04-16 11:52:30

       2006 full year biological and biochemical products industry achieved sales revenue of RMB yuan, an increase of 25.5%, growth rate lower than the end of the previous quarter and the same period last year. From the point of view of profit, the 2006 annual biological and biochemical products industry accumulated profit reached 41.31 billion yuan, the cumulative total profit than last year increase over the same period 5.09 billion yuan, growth has declined compared with the level of the same period last year, slightly higher than that at the end of the quarter. Biological and biochemical products industry the number of loss making enterprises to 103, loss of 20.48%, is slightly lower than that of 21.89% at the end of the season, loss making enterprises accumulated losses reached 5.71 billion yuan, total losses accumulated year-on-year growth reached 76.39%, than at the end of last quarter and last year increase over the same period about 30 percentage points. As of the end of 12, the total assets of biological and biochemical products industry, total liabilities of $, the industry's average asset liability ratio of 43.77%. In 2005 and 2006 the Chinese biotechnology industry development report shows that biopharmaceutical industry in China after nearly 20 years of development, at present existing biological pharmaceutical enterprises more than 400, nearly annual sales income of biotech drugs in two years in more than 240 billion yuan (including a part of in vitro diagnostic kit sales)。

      One、2007 Global biopharmaceutical market growth rate will reach 13%

      In 2007, the global pharmaceutical market will maintain a moderate growth rate. According to the latest research, in 2007, global pharmaceutical sales are expected to grow by 5% to 665 billion, reaching 6% to 685 billion U.S. dollars, down from 6% in 2006 to 7% growth rate. Among them, the demand for biotechnology drugs is expected to grow strongly, the growth rate will reach 13% ~ 14%. Data show that from 2004 to 2010, the average annual growth rate of large pharmaceutical companies in the bio pharmaceutical sales is expected to reach 13%. With the simultaneous growth of biological drugs, is the rapid rise of bio technology apis. The market of raw materials of biological technology is different from that of small molecule drugs, which is mainly used for internal use.

      According to CPA statistics, in 2005, the total demand for biotech raw materials is $7 billion 400 million, is expected to grow to $15 billion 200 million in 2010, an average annual growth rate of 15.5%. In 2005, the five main products accounted for to 50% market share, respectively is red blood cell formation stimulating protein E-SPs, monoclonal antibody (McAb), colony stimulating factor (G-CSFs), recombinant human insulin and human growth hormone (hGH). According to CPA statistics, the United States is the largest producer of bio technology raw materials, annual production value of $, accounting for 57.4% of the total market. North American biotech raw material production is expected to grow to $8 billion 900 million in 2010, an average annual growth rate of 14.4%. Asia Pacific region is expected to become the second largest biotechnology raw material production areas, by 2010 will grow to about $3 billion 600 million, the average annual growth rate of 27.1%, which is mainly based on bio generic drugs. Biological drugs occupy a large share of the sales of prescription drugs in large pharmaceutical companies. Decision resources analyst Andrew G.Merseth expects biosimilars because of erosion, the main four brands of biological drug market will decline, in 2006, the American ESPs, G-CSFs, insulin and insulin analogues and human growth hormone (hGH) class brand-name drugs valued at $9.5 billion, is expected to 2012 will be reduced to $80 billion, by 2015 will be reduced to $38 billion。

      Two、2011 global biopharmaceutical market is expected to reach $98 billion 200 million

      Frost & SullivanOne of the company's latest report said that the current global biopharmaceutical market revenue of $45 billion, in 2011 is expected to reach $98 billion 200 million. Despite the increasing world demand for biological drugs, but due to the traditional mode of production (microbial and mammalian fermentation system), production cost remains high. However, the use of genetically modified plants as a recombinant protein and other biological drugs production platform may greatly improve the production scale and production, thereby significantly reducing the cost of production. With the gradual improvement of public awareness and related laws and regulations, the use of genetically modified plants to produce biological drugs market will grow rapidly, by 2011 alone the United States market will reach $2 billion 200 million.

      Three、At present, the development of the global bio pharmaceutical industry is extremely unbalanced.

      First, the level of development of bio pharmaceutical industry in various countries is very uneven; the two is the development of biotechnology drugs is very uneven. The development of bio pharmaceutical industry is mainly determined by the national science and technology strength and people's living standard. In 1993, North America (mainly the United States), bio pharmaceutical industry in the European Union and Japan almost three pillars, in a total of $84 billion market share in each accounted for 20 to 30 billion dollars. But after 10 years of development, the United States is far behind the other countries, its biotech drugs accounted for 58% of the global pharmaceutical market, and the proportion is still expanding. And the European Union after the recent 5 years of development, is catching up with the United States, its share reached 22%. Japan's bio pharmaceutical development is lagging behind and stagnant. In other countries and regions, bio pharmaceutical is basically in its initial stage. China's bio pharmaceutical research, development and production and other key technologies, such as the United States and the United States there is a considerable gap. According to statistics, at present, 10% of biotech drugs accounted for 90% of the entire biopharmaceutical market. In the United States, the European Union and other major bio pharmaceutical companies approved the listing of more than 500 kinds of biotech drugs, ranking the top 10 products accounted for more than 50% of the entire bio pharmaceutical market. In the first 50 kinds of products, animal products, both from the number or from the sales point of view are accounted for 65% ~ 70% 。

      Four、The process of bio pharmaceutical industry is accelerating, and the market scale is expanding rapidly.

      Over the past 20 years to gene engineering, cell engineering, enzyme engineering as the representative of the rapid development of modern biological technology and human genome project major technological breakthrough after another, modern biotechnology in medical treatment is widely used, bio medicine industrialization process has accelerated noticeably. More than 2200 biotech drugs are developed in the world, including more than 1700 species in clinical trials. The rapid increase in the number of biotech drugs indicates that in twenty-first Century the world pharmaceutical biotechnology industry is gradually entering the harvest period, the rapid growth of the global bio pharmaceutical industry. Since 90s of last century, global sales of biological drugs with an average annual growth rate of more than 30%, significantly higher than the global pharmaceutical industry average annual growth rate of less than 10%. Global biotech industry's annual sales of approximately $45 billion, of which about 40 billion U.S. dollars of biological and pharmaceutical sales. Bio pharmaceutical industry is rapidly from the most development potential of high-tech industries to high-tech pillar industry development。

      Five、The development of biological medicine showed a significant trend in the market concentration and product concentration, and the developed countries occupy the leading position.

      First, a small number of developed countries in the global bio pharmaceutical market in the industry leading position. In the world drug market, the United States, Europe, Japan, the three largest drug market share of more than 80%. From the perspective of the biotechnology industry, the total number of biotechnology companies worldwide reached 4362, total sales of about $413 billion, which total number of biotechnology companies mainly concentrated in Europe and the United States, accounting for 76% of the global total, Europe's sales accounted for 93% of the global biotechnology company sales, and sales in the Asia Pacific region accounted for only in the world of 3%. The United States is a leading biotechnology industry, far ahead of other countries, the development of its products and market sales accounted for more than 70% of the global. Two is a large multinational companies dominate the world's patent medicine market. These multinational enterprises in the global pharmaceutical market in the rising status, the proportion of the growing. Since 1994, the world's top twenty pharmaceutical enterprises accounted for 50% of the global pharmaceutical market, rose to 66% in 2002, the concentration of the modern pharmaceutical industry increased year by year, the degree of monopoly of multinational companies continue to increase. Three is in the product market, the market concentration of single species sales also showed a rising trend. The world's top selling 10 kinds of drugs, the total sales of nearly 40 billion yuan, accounting for the annual global drug sales of 1/10. This concentration of the market will not change in the short term。

      Six、Traditional medicine products still dominate, pharmaceutical biotechnology and natural medicine prospects

      Due to a number of heavyweight product driven, the demand for antibiotics is still showing growth, overall speaking, the next few years, the traditional chemical drug market is still huge, about 70% of the entire pharmaceutical market. Due to the rapid development of biotechnology and medicine consumption structure change and drug safety performance requirements and chemicals in the drug market dominance is being seriously challenged, biological class of emerging drugs will be in the pharmaceutical market in the rapid rise, biological drugs has become the top priority for the drug development. At the same time, more and more new and high technology and biotechnology will be applied to the germplasm improvement of natural medicinal herbs, natural drugs will be more rapid growth. Predicted that by 2010, the share of biological drugs will increase to more than 18%, the market share of natural drugs will increase to about 7%。

      Seven、Developed countries have formed a number of bio pharmaceutical industry intensive areas

      In the wave of the rapid development of biotechnology industry to promote, through years of development and competition in the market, the government to seize the opportunity and to be guided, many developed countries in the areas of technology, talent, capital intensive, has gradually formed the biological industry gathering area, thus forming a relatively complete bio pharmaceutical industry chain and industrial cluster. The United States has formed in San Francisco, Boston, Washington, North Carolina, five San Diego Biotechnology Industrial zone. Which accounted for more than half of the US biotechnology industry practitioners practitioners of the biotechnology industry in Silicon Valley, the sales revenue accounted for 57% of the biotechnology industry in the United States, R & D investment accounted for 59% and its annual sales of nearly 40% of the rate of growth. Outside the US, gene Valley, Cambridge genome Park, the southern suburbs of Paris, France, Germany's bio technology demonstration area in Bangalore, India, the biological park, gathered including biotechnology company, research, technology transfer center, banking, investment, services and other large institutions, provides a large number of employment opportunities and most of the output value. The biotechnology industry cluster has been in the industrial structure in these countries and regions emerge, to expand the industrial scale, enhance industrial competitiveness and make an important contribution to。

      Eight、Strategic technology alliance has become a successful model for new drug development

      Drug discovery is a integration of molecular biology, genomics, systems biology knowledge and technology, complex systems engineering, pre huge investment, the risk is very big, need to between multinational pharmaceutical giant, biotechnology companies and pharmaceutical companies alliance and joint investment. According to the data, half of the biotech drugs approved in 2000 have been developed successfully by means of cooperation. The trend of strengthening cooperation is mainly in: First, the strategic alliance to promote biotechnology to industrial transformation. Due to master the most biotechnology products and production technology in the hands of a new biotechnology company, to maintain continuity of new drug R & D, almost all pharmaceutical companies are with biotechnology companies formed a strategic alliance, technology development and innovation by these strong technical force of expert type small biotech companies and development through cooperation, access to the pharmaceutical and biological production technologies or production in, this model contributed to the success the benign development of the bio pharmaceutical industry. Two is the innovation of drug development using the outsourcing strategy. In order to shorten the time of new drug development, in recent years many biotechnology and pharmaceutical companies began and a number of small companies form technology alliance, technology research and development of content, subcontracted to completed with the strength of the small companies